347 related articles for article (PubMed ID: 18056893)
41. Insulin therapy for type 2 diabetes mellitus.
Wallia A; Molitch ME
JAMA; 2014 Jun; 311(22):2315-25. PubMed ID: 24915263
[TBL] [Abstract][Full Text] [Related]
42. Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinical Trial Database.
Bae JP; Duan R; Fu H; Hoogwerf BJ
Clin Ther; 2017 Sep; 39(9):1790-1798.e7. PubMed ID: 28781218
[TBL] [Abstract][Full Text] [Related]
43. Use and Discontinuation of Insulin Treatment Among Adults Aged 75 to 79 Years With Type 2 Diabetes.
Weiner JZ; Gopalan A; Mishra P; Lipska KJ; Huang ES; Laiteerapong N; Karter AJ; Grant RW
JAMA Intern Med; 2019 Dec; 179(12):1633-1641. PubMed ID: 31545376
[TBL] [Abstract][Full Text] [Related]
44. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
Garber AJ; Clauson P; Pedersen CB; Kølendorf K
J Am Geriatr Soc; 2007 Nov; 55(11):1735-40. PubMed ID: 17979896
[TBL] [Abstract][Full Text] [Related]
45. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs.
Signorovitch JE; Macaulay D; Diener M; Yan Y; Wu EQ; Gruenberger JB; Frier BM
Diabetes Obes Metab; 2013 Apr; 15(4):335-41. PubMed ID: 23121373
[TBL] [Abstract][Full Text] [Related]
46. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study.
Huang ES; Liu JY; Moffet HH; John PM; Karter AJ
Diabetes Care; 2011 Jun; 34(6):1329-36. PubMed ID: 21505211
[TBL] [Abstract][Full Text] [Related]
47. Insulin Sensitivity and Diabetic Kidney Disease in Children and Adolescents With Type 2 Diabetes: An Observational Analysis of Data From the TODAY Clinical Trial.
Bjornstad P; Nehus E; El Ghormli L; Bacha F; Libman IM; McKay S; Willi SM; Laffel L; Arslanian S; Nadeau KJ;
Am J Kidney Dis; 2018 Jan; 71(1):65-74. PubMed ID: 29157731
[TBL] [Abstract][Full Text] [Related]
48. Association of Potentially Modifiable Diabetes Care Factors With Glycemic Control in Patients With Insulin-Treated Type 2 Diabetes.
Lauffenburger JC; Lewey J; Jan S; Lee J; Ghazinouri R; Choudhry NK
JAMA Netw Open; 2020 Jan; 3(1):e1919645. PubMed ID: 31968115
[TBL] [Abstract][Full Text] [Related]
49. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
Yurgin N; Secnik K; Lage MJ
Clin Ther; 2007 Feb; 29(2):316-25. PubMed ID: 17472823
[TBL] [Abstract][Full Text] [Related]
50. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus.
Ceglia L; Lau J; Pittas AG
Ann Intern Med; 2006 Nov; 145(9):665-75. PubMed ID: 17088580
[TBL] [Abstract][Full Text] [Related]
51. Type 2 diabetes: target HbA1c of about 7%.
Prescrire Int; 2009 Aug; 18(102):177. PubMed ID: 19746575
[TBL] [Abstract][Full Text] [Related]
52. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial.
Rosenstock J; Zinman B; Murphy LJ; Clement SC; Moore P; Bowering CK; Hendler R; Lan SP; Cefalu WT
Ann Intern Med; 2005 Oct; 143(8):549-58. PubMed ID: 16230721
[TBL] [Abstract][Full Text] [Related]
53. Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort.
; Gubitosi-Klug RA; Sun W; Cleary PA; Braffett BH; Aiello LP; Das A; Tamborlane W; Klein R
JAMA Ophthalmol; 2016 Feb; 134(2):137-45. PubMed ID: 26584339
[TBL] [Abstract][Full Text] [Related]
54. Preoperative insulin therapy as a marker for type 2 diabetes remission in obese patients after bariatric surgery.
Hariri K; Guevara D; Jayaram A; Kini SU; Herron DM; Fernandez-Ranvier G
Surg Obes Relat Dis; 2018 Mar; 14(3):332-337. PubMed ID: 29339030
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
[TBL] [Abstract][Full Text] [Related]
56. [Not Available].
Zulewski H
Ther Umsch; 2017; 74(8):411-416. PubMed ID: 29461143
[No Abstract] [Full Text] [Related]
57. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%.
Pani LN; Nathan DM; Grant RW
Diabetes Care; 2008 Mar; 31(3):386-90. PubMed ID: 18083790
[TBL] [Abstract][Full Text] [Related]
58. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
[TBL] [Abstract][Full Text] [Related]
59. Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk.
Wareham NJ; Pfister R
Nat Rev Cardiol; 2010 Jul; 7(7):367-8. PubMed ID: 20577298
[TBL] [Abstract][Full Text] [Related]
60. The relationship between glycemic control and falls in older adults.
Nelson JM; Dufraux K; Cook PF
J Am Geriatr Soc; 2007 Dec; 55(12):2041-4. PubMed ID: 17971138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
